Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
- Conditions
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 613
- Registration Number
- NCT00485589
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
- Conditions
- Interventions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT00476996
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Center For Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Arthritis Consultants, Saint Louis, Missouri, United States
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT00406419
- Locations
- 🇺🇸
Trial Information Support Line, South San Francisco, California, United States
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-09-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00077870
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.